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Background: Colorectal cancer (CRC) is the fourth leading cause of cancer-related death in Europe and the United
States. Detecting the disease at an early stage improves outcomes. Risk prediction models which combine multiple
risk factors and symptoms have the potential to improve timely diagnosis. The aim of this review is to
systematically identify and compare the performance of models that predict the risk of primary CRC among
symptomatic individuals.
Methods: We searched Medline and EMBASE to identify primary research studies reporting, validating or
assessing the impact of models. For inclusion, models needed to assess a combination of risk factors that
included symptoms, present data on model performance, and be applicable to the general population.
Screening of studies for inclusion and data extraction were completed independently by at least two
researchers.
Results: Twelve thousand eight hundred eight papers were identified from the literature search and three
through citation searching. 18 papers describing 15 risk models were included. Nine were developed in primary
care populations and six in secondary care. Four had good discrimination (AUROC > 0.8) in external validation
studies, and sensitivity and specificity ranged from 0.25 and 0.99 to 0.99 and 0.46 depending on the cut-off
chosen.
Conclusions: Models with good discrimination have been developed in both primary and secondary care
populations. Most contain variables that are easily obtainable in a single consultation, but further research is
needed to assess clinical utility before they are incorporated into practice.
Keywords: Colorectal cancer, Risk, Model, Symptoms, PredictionBackground
Colorectal cancer (CRC) is the third most common cancer
worldwide and the fourth leading cause of cancer-related
death [1]. Detecting the disease at an early stage improves
outcomes [2]. Whilst screening has been successful in re-
ducing the incidence and mortality of CRC by increasing
the proportion diagnosed at an early stage and facilitating
removal of pre-neoplastic lesions [3–5], the majority of
cancers are still diagnosed after symptomatic presentation
[6]. Three previous meta-analyses have shown that indi-
vidual symptoms, such as rectal bleeding and change in* Correspondence: jau20@medschl.cam.ac.uk
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(http://creativecommons.org/publicdomain/zebowel habit, are associated with CRC, but are also
common in populations without cancer and so have poor
sensitivity for CRC [7–9]. Consequently, identifying which
patients from primary care should be referred for diagnos-
tic investigation remains challenging.
Several approaches have been developed to improve
the appropriateness of referrals for investigation of
symptoms suggestive of CRC and reduce delays in diag-
nosis. The NHS in England introduced the two-week
wait (2WW) referral system in 2000, followed by the
NICE suspected cancer referral guidelines in 2005 which
have been recently updated [10]. A number of evalua-
tions have shown that the 2WW referral system for sus-
pected CRC has variable sensitivity and low specificity
and does not improve diagnostic accuracy [9, 11–16]. Inle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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veloped to identify people at higher risk of CRC
among those with symptoms. These have the potential to
improve the consistency and quality of clinical decision-
making. However, their strengths, weaknesses and relative
performance are uncertain, and few direct comparisons
have been made. The aim of this review was to systematic-
ally identify and compare the performance of models that
predict the risk of undiagnosed prevalent primary
CRC for symptomatic individuals.
Methods
We performed a systematic literature review following
an a priori established study protocol (available on
request) that followed the PRISMA guidelines (see
Additional file 1 for the PRISMA checklist).
Search strategy
We used a combination of subject headings including
‘colorectal cancer’, ‘risk/risk factor/risk assessment/chance’
and ‘prediction/model/score’ to conduct an electronic
literature search within Medline and EMBASE. The
search period ran from January 2000 to March 2014
(see Additional file 2 for the complete search strategy
for Medline and EMBASE). We subsequently hand
searched the reference lists of all included papers. We
also considered for inclusion papers published before
2000 describing the development of models that were
validated in included papers.
Study selection
To be included, studies had to be published as a primary
research paper in a peer-reviewed journal and either de-
scribe, validate or assess the impact of a risk model that
allowed identification of people at higher risk of CRC or
CRC and advanced colorectal neoplasia. The risk model
had to feature two or more risk factors, including symp-
toms, for prevalent undiagnosed colorectal cancer at the
level of the individual. In addition, a quantitative measure
of model performance was required. Conference proceed-
ings, papers not in English, and studies of a specific pa-
tient group, for example immunosuppressed patients or
patients with a past history of CRC, were excluded.
One reviewer (JUS) screened the titles and abstracts of
papers identified by the Medline and EMBASE searches
to exclude studies that were clearly not relevant. A sec-
ond reviewer (TGSW) independently assessed a random
selection of 10 % of the papers at title and abstract level
and both reviewers (TGSW and JUS) independently
assessed all the full text of papers if a definite decision
to reject could not be made based on title and abstract
alone. All reviewers met to discuss discrepancies and
reach a consensus decision on inclusion or exclusion.Data extraction and synthesis
Two reviewers (TGSW and JC) extracted data from each
paper using a standardised form. Discrepancies were
examined and resolved by a third reviewer (JUS). We
extracted information on the components of each risk
model and potential sources of bias. These included:
study design and participants; methods of model develop-
ment; and variables included in the risk model. The
methods of studies published for each risk model was also
classified according to the TRIPOD guidelines (1a-De-
velopment only; 1b-Development and validation using
resampling; 2a-Random split-sample development and
validation; 2b-Non-random split-sample development
and validation; 3-Development and validation using
separate data; 4-Validation study) [17]. Where multiple
models were described within the same study, each model
was included separately.
Reported measures of discrimination (area under the
receiver operating characteristic curve (AUROC)), accur-
acy (sensitivity and specificity), calibration and utility
were used to compare the performance of different
risk models and thresholds in development and valid-
ation populations. Numerical values for the AUROC
were used to compare discrimination and the sensitivity
and specificity to compare the accuracy, of different
models and thresholds. For those papers in which
sensitivity and specificity were not reported explicitly,
where possible we calculated the values from data
provided in the paper. Figures were produced using
RevMan version 5.3 and where multiple studies
reported the sensitivity and specificity of the same
model at the same threshold, the combined values
were calculated using Meta-DiSc version 1.4.
Quality assessment
Quality assessment was performed at the same time as
data extraction. Since our review included studies with
different designs we used a checklist based on the Critical
Appraisal Skills Programme guidelines for case-control
and cohort studies [18] as an initial framework, and then
classified each study as high, medium or low quality. No
studies were excluded based on quality assessment alone.
Results
Included studies
After duplicates were removed, the search identified
12,808 papers of which 12,765 were excluded at title and
abstract level. A further 29 were excluded after full-text
assessment by at least two reviewers (TGSW and JUS).
There was complete agreement among researchers
throughout the screening process. The most common rea-
sons for exclusion were that the papers did not report a
statistical measure of model performance (n = 9), only eval-
uated one predictor (n = 6), or were conference abstracts
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ation searching, including one published prior to 2000
which was included as it had been externally validated in
one of the papers identified through the literature search.
In total we included 18 papers describing 15 risk prediction
models in the review (Fig. 1). Only one paper assessed the
impact of one of the models in practice [19].
A summary of the quality assessment of each of
the 18 papers is given in Table 1. Eleven were
assessed as high quality, four as medium quality and
three as low quality. The studies assessed as low
quality were two cross-sectional studies recruiting
patients presenting to either primary or secondary
care with rectal bleeding [20, 21], and the single
study assessing model impact [19].
Risk model development and validation
Table 1 also summarizes the methods used to develop
and validate the models. Of the 15 included models, nine
were developed in primary care populations [21–27] andFig. 1 PRISMA flow diagramsix in secondary care [20, 28–32]. Most (n = 11) had
CRC as a single outcome, whilst two in secondary care pre-
dicted CRC combined with advanced adenoma (a polyp
measuring 10 mm or bigger, or a polyp of any size with a
villous histology [20]) or pre-malignant adenomas [28].
The remaining two reported CRC risk alongside the risk of
cancers of several other sites [26, 27].
Most models were developed from either cross sec-
tional (n = 6), prospective cohort (n = 4) or case-
control studies (n = 4), with one developed based on
clinical experience [30]. Four used self-administered
questionnaires or interviews conducted by non-
medically trained staff to gather information. The
remaining 11 models required the input of a health-
care worker. Nine of the 15 models have been vali-
dated: one using bootstrap resampling [32]; two using
a random split-sample [26, 27]; and six in external
populations [21, 24, 25, 30]. Details of the methods
and study populations for the validation studies are
also given in Table 1.
Table 1 Summary of quality assessment and study design for the 18 included papers
Author, date,
country, setting
Qualityf Outcome Data collection Selection of
variables
Identification of
study population
Identification of
outcome cases
Exclusions Study population
Model development; Case-control studies
Cases Controls Cases Controls
Hamilton, 2005, UK,
primary care [22]
M CRC Primary care
records from
21 practices
Occurring in
at least 2.5 %
of cases or
controls
>40 years
with
primary
CRC
5 controls per case
matched for sex,
general practice
and age and alive
at point of case
diagnosis
Cancer registry at
one hospital
Unobtainable records,
no consultations in
2 years before diagnosis,
previous CRC, residence
outside Exeter at time
of diagnosis.
349 1,744
Hamilton, 2009, UK,
primary care [23]
M CRC THIN database Literature
review
> 30 years
with CRC
Up to 7 controls
without CRC
matched for practice,
sex and age
Diagnosis of CRC
within study
period
< 2 years of full electronic
records before date of
case diagnosis.
5,477 38,314
Model development and external validation; Case-control study
Cases Controls Cases Controls
Marshall, 2011, UK,
primary care [24]
H CRC BB equation development and CAPER Score external validation
See Hamilton, 2009 [23] As in Hamilton, 2009 plus
patients with severe
anaemia (Hb < 10 g/dl),
rectal bleeding, abnormal
rectal examination or
positive FOBT, or without
any of abdominal pain,
weight loss, diarrhoea or
constipation
117 433
CRC CAPER Score development and BB equation external validation
See Hamilton, 2005 [22]
Model development and random split-sample internal validation; Cohort studies
Included Cases
(% of
included)
Hippisley-Cox, 2012,
UK, primary care
(QCancer®
(colon)) [25]
H CRC QResearch
database
'Established
predictor
variables' and
red flag
symptoms
30–84 year-old patients
registered with practices
between 1/1/2000 and
30/09/2010 and without
CRC
Incident cancer
diagnosis in the
2 years after cohort
entry recorded in
GP records or ONS
cause-of-death
record
History of CRC, recorded
red flag symptomf in the
12 months preceding
the study date, or missing
Townsend deprivation
score.
Development
F: 1,172,670 F:4,798
(0.2 %)
M:1,178,382 M:4,798
(0.2 %)
Internal validation
F: 616,361 F: 2603
(0.2 %)
M: 620,240 M:2603
(0.2 %)
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Table 1 Summary of quality assessment and study design for the 18 included papers (Continued)
Hippisley-Cox, 2013
(female), UK, primary care
(QCancer® (combined)) [26]
H CRC and 11
other cancersa
QResearch
database
Previous study,
and literature
review
25–89 year-old
patients registered
with practices
between 1/1/2000
and 1/04/2012 and
without CRC
Incident cancer
diagnosis in the
2 years after cohort
entry recorded in
GP records or ONS
cause-of-death
record
Recorded red flag
symptomf in the 12
months before the
study entry date, or
missing Townsend
deprivation score.
Development
1,240,864 2607
(0.18 %)
Internal validation
679,174 1725
(0.25 %)
Hippisley-Cox, 2013 (male), UK,
primary care
(QCancer® (combined)) [27]
H CRC and 9 other
cancersb
QResearch
database
Previous study,
and literature
review
25–89 year-old
patients registered
with practices
between 1/1/2000
and 1/04/2012 and
without CRC
Incident cancer
diagnosis in the
2 years after cohort
entry recorded in
GP records or ONS
cause-of-death
record
Recorded red flag
symptomf in the 12
months before the
study entry date, or
missing Townsend
deprivation score.
Development
1,263,071 3250
(0.26 %)
Internal validation
667,603 1356
(0.2 %)
Model development; Cross-sectional studies
Included Cases
(% of
included)
Adelstein, 2010, Australia,
secondary care [32]
H CRC Self-administered
questionnaire
Not reported Patients > 18 years
old scheduled for
colonoscopy at
hospitals
Complete
colonoscopy
and histology
Completion of
questionnaire
> 6 months before
colonoscopy, advanced
adenomac, incomplete
colon evaluation
7,736 159
(2.1 %)
Adelstein, 2011, Australia,
secondary care [31]
H CRC See Adelstein
2010 [32]
Completion of
questionnaire
> 6 months before
colonoscopy, adenomad,
incomplete colon
evaluation
6943 159
(2.3 %)
Fijten, 1995, Netherlands,
primary care [21]
L CRC Patient and doctor
questionnaires, and
blood sample
Literature
review
Patients presenting
to 83 GP practices
with overt rectal
bleeding or a
history of visible
rectal blood loss in
previous 3 months.
Medical record
review coded
using the
International
Classification of
Primary Care
for diagnostic
classification
Patients aged <18 or
>75, pregnancy, urgent
admission to hospital
or follow-up not
available.
290 9 (3.4 %)
Hurst, 2007, UK, secondary
care [28]
M CRC or pre-
malignant
adenomas
Proforma-based
history, examination
and blood sample
Not reported All adult patients
referred to a
specialist colorectal
clinic
Patients tracked
until a definitive
diagnosis was
reached
Patients not further
investigated after
initial consultation
or who did not
attend follow up
300 95
(31.7 %)
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Table 1 Summary of quality assessment and study design for the 18 included papers (Continued)
Lam, 2002, Hong Kong,
secondary care [20]
L CRC or significant
neoplasiae
Questionnaire
conducted by
non-medically
trained interviewers
Not reported New patients
attending surgical
department for
rectal bleeding
Rigid sigmoidoscopy
and proctoscopy,
followed by barium
enema or colonoscopy
at the physician's
discretion
Refusal for colonoscopy
or barium enema
174 29
(16.7 %)
Mahadavan, 2011, UK,
secondary care [29]
M CRC Self-administered
questionnaire,
history, faecal,
blood and rectal
samples
Not reported All patients >40
years referred to
a surgical clinic
via the 2wwg
system for
colorectal cancer
Incident diagnosis
of CRC within 6
months of study
entry from primary
care or hospital
records confirmed
histologically
Previous confirmed
IBD, GI cancer,
investigation of the
bowel within the last
6 months or absent
rectal sampling result
714 72
(10.1 %)
Model development and external validation; Cross-sectional study
Included Cases
(% of
included)
Selvachandran, 2002, UK,
secondary care (WNS)
[30] h
H CRC Self-administered
questionnaire
Not reported Patients referred
by GPs with
symptoms
suggestive of
distal colonic or
anorectal disease
Not reported
(all patient's
received
endoscopy)
Not reported 2,268 95 (4.2 %)
Model external validation; Cohort study
Model(s)
validated
Included Cases
(% of
included)
Collins, 2012, UK,
primary care [33]
H QCancer® (colon)
(female and
male) [25]
THIN database N/A 30–84 year-old
patients registered
with practices
between 1/1/2000
and 30/09/2010
and without CRC
Incident cancer
diagnosis of CRC
in the 2 years
after cohort entry
Patients with a history
of CRC, a recorded
red flag symptomf
in the 12 months
preceding the study
date, registered
<12 months with
practice or with
invalid dates
Female:
1,075,775
Female:
1,676
(0.15 %)
Male:
1,059,765
Male:
2,036
(0.19 %)
Model external validation; Cross-sectional studies
Model(s)
Validated
Included
(% of
eligible)
Cases
(% of
included)
Ballal, 2009, UK,
secondary care [35]
H WNS [30] Self-administered
questionnaire
N/A Patients with
colorectal
symptoms
referred by GPs
A combination of
rigid sigmoidoscopy,
flexible sigmoidoscopy,
colonoscopy or
barium enema
Patients thought (on
the basis of the referral)
most likely to have
right-sided CRC, or but
did not attend for
investigation
3,457 186
(5.4 %)
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Table 1 Summary of quality assessment and study design for the 18 included papers (Continued)
Hodder, 2005, UK,
secondary care [34]
H WNS [30], Fijten
1995 [21]
Self-administered
questionnaire
N/A Patients referred
from primary care
with colorectal
symptoms
Secondary care
investigations -
minimum flexible
sigmoidoscopy
Not reported 3,302 156
(4.7 %)
Rai, 2008, UK, secondary
care [11]
H WNS [30] Self-administered
questionnaire
N/A GP referral with any
of: lower bowel-
related symptoms,
unexplained iron
deficiency anaemia,
positive FOBT, or
palpable rectal/
abdominal mass
Follow up during
course of hospital
investigations until
a final diagnosis
made
Patients admitted
hospital as an
emergency and
subsequently
diagnosed with
CRC
1,422 83
(5.84 %)
Model utility; cohort study
Model used Outcome measures Included Interviews
Hamilton, 2013, UK,
primary care [19]
L Hamilton 2005
[22]
GP usage and
outcomes from
practices and
local trusts;
qualitative
interviews
Not reported Risk assessment
tools (RATs) supplied
to 614 GPs at 164
practices for 6 months;
interviews with GP
cancer network leads
and sample of GP
users from practices
with differing patient
demographics.
Number of 2WW
referrals and
colonoscopies for
patients >40;
symptoms used
in RATs; qualitative
interview data.
RATs performed
on patients <40;
RATs that did not
identify the reported
symptoms.
1433 23 GP
responders
CRC colorectal cancer, ONS office of national statistics, FOBT faecal occult blood test, IBD Inflammatory bowel disease, Hb haemoglobin, WNS Weighted Numerical Score developed by Selvachandran 2002 [30], RAT risk
assessment tool
aLung, gastro-oesophageal, pancreatic, renal tract, haematological, breast, ovarian, uterine, cervical and other cancer
bLung, gastro-oesophageal, pancreatic, renal tract, haematological, prostate, testicular, and other cancer
cAdenoma with significant (> 25 %) villous features, or high grade dysplasia, including carcinoma-in-situ, or size 10 mm or larger
dAdenoma of any size or histology
ePolyp 10 mm or larger, or a polyp of any size with a villous histology
frectal bleeding, weight loss, abdominal pain, loss of appetite
g2WW - Two week wait
hThe method of developing the WNS is copyrighted and incompletely reported
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We categorized risk factor variables into five types: demo-
graphic, personal and family medical history, symptoms,
signs, and investigations (Table 2). Seventeen variables
were included in three or more models: four demographic
variables (age, sex, smoking, alcohol); family history of
CRC; eight symptoms (rectal bleeding, change in bowel
habit, diarrhoea, constipation, abdominal pain, weight
loss, loss of appetite, mucous in the stool); abnormal rectal
examination; and three investigations (haemoglobin, mean
cell volume, faecal occult blood testing). All models in-
cluded symptoms, four included only symptoms [22–24],
and most also included age (n = 11) and sex (n = 9). The
choice of variable in each model was often influenced by
the study design. For example, the Hamilton et al. 2005
risk model [22] and the CAPER score [24] were developed
from case-control studies using primary care records and
include symptoms plus additional signs and investigations
without any demographic information or personal or fam-
ily medical history. In contrast, the models developed by
Adelstein [31, 32] from patient-completed questionnaires
include symptoms plus demographic information and per-
sonal or family medical history.
Performance of risk models
Accuracy
Sensitivity and specificity were reported for 11 of the 15
models in either development populations (n = 5), in
random split-sample internal validation (n = 2), random
split-sample internal validation and external populations
(n = 2) or in external populations (n = 2); for four models
these were provided for multiple thresholds. These values
are summarized in Fig. 2 in which models are divided into
those developed (and validated) in primary care, and those
developed (and validated) in secondary care.
At all selected risk thresholds the seven models devel-
oped in primary care populations achieved high specificity
(range 0.90–0.98), whilst the sensitivity ranged from 0.25
for the QCancer® (colon) model [25] with the threshold
set at the top 1 % in internal validation, to 1.00 for
the Fijten et al. model developed from a cohort of patients
presenting to primary care practices in the Netherlands
with rectal bleeding that contained only nine CRC cases
[21]. Information on sensitivity and specificity of three
models developed in primary care was reported in exter-
nal cohorts: the CAPER score [24] and the two QCancer®
(colon) models for male and female individuals [33].
Whilst all three models had similarly high specificity, the
QCancer® (colon) models had higher sensitivity at all
thresholds used for external validation and performed
better in males then females.
Only one model developed in secondary care, the
Weighted numerical scoring system (WNS) [30], has been
externally validated. Four studies reported the sensitivityand specificity at four different thresholds (a score of 40,
50, 60 or 70). As expected, the lowest threshold of 40 had
the highest pooled sensitivity (0.96 (95 % C.I. 0.93–0.97),
n = 4 studies) and the lowest pooled specificity (0.40 (95 %
C.I. 0.39–0.41), n = 4 studies), whilst the threshold of 70
had values comparable to those in primary care with a
lower sensitivity of 0.64 (95 % C.I. 0.53–0.74) (n = 3) and
higher specificity of 0.82 (95 % C.I. 0.81–0.83) (n = 3).
Discrimination
The discriminatory performance of 11 of the 16 models
was reported as the AUROC. As shown in Fig. 3, these
range from 0.83 to 0.97 in model development populations,
0.89 to 0.91 in internal validation studies, and 0.76 to 0.92
in external validation studies. The highest discriminatory
performance (AUROC 0.97) was achieved by the model
developed by Fijten et al. in patients presenting to primary
care practices in the Netherlands with rectal bleeding [21].
However, in an external validation study of the model in
secondary care the discrimination fell to 0.78 [34]. The
models demonstrating the best discrimination in external
validation studies were the BB equation developed by
Marshall et al. using a case-control design in the The
Health Improvement Network (THIN) database of English
primary care records [24] and the QCancer® (colon) male
and female models developed from a cohort within the
QResearch database of English primary care records [25].
Other performance measures and utility
Three models reported performance as positive predictive
values (PPVs): the model by Lam et al. with a combined
outcome of CRC or a polyp measuring 1 cm or bigger or
any size with a villous histology derived in Hong Kong
from a secondary care population in which PPVs ranged
from 4.5 to 33.6 % [20], and the models developed by
Hamilton et al. in the UK from primary care populations
with PPVs ranging from 0.42 to 11 % [22], and from 0.04
to 4.5 % [23].
No studies reported numerical measures of calibration
but Hippisley-Cox et al. 2012 showed plots of observed
and predicted risk for the male and female QCancer®
(colon) models in internal validation and these show
overall good calibration [25].
Only one study assessed the utility of a risk model in
practice: the risk score developed by Hamilton et al.
2009 [23] was assessed alongside a risk score for lung
cancer in 165 UK general practices [19]. Paper, mouse-
mat and desktop easel forms displaying the risk
models were provided for a six month period. During
this time there was an increase in cancer diagnostic
activity, urgent referrals and cancer diagnoses when
compared with the previous six months but as it was
not a trial it is not possible to say whether these
changes were due to the use of the risk model.
Table 2 Variables included in risk models and TRIPOD classification of studies examining model performance
Author, year TRIPOD
levela
Demographic variables Personal and Family Medical History Symptoms
Age Sex Smoking Alcohol Other Family history
of GI cancer
Other Rectal
bleeding
Change in
bowel habit
Diarrhoea Constipation Abdominal
pain
Models predicting gastrointestinal cancers and neoplasms
Adelstein, 2010 [32] 1b ● ● Colonoscopy in last 10 years;
history of diverticular disease,
NSAID use, or aspirin use.
● ●
Adelstein, 2011 [31] 1a ● ● ● Education level. Colonoscopy in last 10 years;
history of colorectal polyps,
IBS, NSAID use or aspirin use.
●
Fijten, 1995 [21] 1a, 4 ● ●d ●
Hamilton, 2005 [22] 1a ● ● ●
Hamilton, 2009 [23] 1a ● ● ● ● ●
Hippisley-Cox, 2012 (Male) [25] 2a, 4 ● N/
A
● ● ● ● ●
Hippisley-Cox, 2012 (Female) [25] 2a, 4 ● N/
A
● ● ●
Hurst, 2007 [28] 1a ● ● ● ●
Lam, 2002 [20] 1a ● ●e
Mahadavan, 2011 [29] 1a ● ● ●
Marshall, 2011 (BB equation) [24] 3 ● ● ●f ●f ●f
Marshall, 2011 (CAPER score) [24] 4 ● ● ●
Selvachandran, 2002 (WNS) [30] c 4, 4, 4,
4
● ● ‘Family history’, ‘relevant
medical history’.
● ●
Models predicting cancers of multiple organ systems alongside colorectal cancer
Hippisley-Cox, 2013 (Male) [27] 2a ● N/
A
● ● BMI; Townsend
deprivation score.
● History of chronic pancreatitis,
type 2 diabetes, or COPD;
family history of prostate cancer.
● ● ● ●
Hippisley-Cox, 2013 (Female) [26] 2a ● N/
A
● ● BMI; Townsend
deprivation score.
● History of chronic pancreatitis,
type 2 diabetes, COPD, or
endometrial hyperplasia/polyps;
family history of breast cancer
or ovarian cancer.
● ● ● ●
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Table 2 Variables included in risk models and TRIPOD classification of studies examining model performance (Continued)
Author, year Symptoms Signs Investigations
Weight
loss
Loss of
appetite
Mucous Other Abnor mal rectal
examination
Other Haemoglobinb MCV FOBT Other
Models predicting gastrointestinal cancers and neoplasms
Adelstein, 2010 [32] ● Anaemiab.
Adelstein, 2011 [31] ● Anaemiab; fatigue.
Fijten, 1995 [21]
Hamilton, 2005 [22] ● ● Abdominal
tenderness
● ● Blood
glucose
Hamilton, 2009 [23] ● ● ●
Hippisley-Cox, 2012 (Male) [25] ● ● ●
Hippisley-Cox, 2012 (Female) [25] ● ● ●
Hurst, 2007 [28] ● sMMP-9
Lam, 2002 [20] ●
Mahadavan, 2011 [29] ● ● eDNA;
CEA
Marshall, 2011 (BB equation) [24] ● ● Abdominal mass ● ● ●
Marshall, 2011 (CAPER score) [24] ● ● Abdominal mass ●
Selvachandran, 2002 (WNS) [30] c ● ● Tenesmus; urgency; incomplete emptying;
perianal symptoms; ‘abdominal symptoms’; tiredness.
Models predicting cancers of multiple organ systems alongside colorectal cancer
Hippisley-Cox, 2013 (Male) [27] ● ● Abdominal distension; heartburn; indigestion;
dysphagia, haematemesis; haematuria; haemoptysis;
neck lump; Night sweats; testicular lump; testicular
pain; first occurrence of a venous thromboembolism;
bruising; cough; impotence; nocturia; urinary frequency;
urinary retention.
●
Hippisley-Cox, 2013 (Female) [26] ● ● Abdominal distension; heartburn; indigestion;
dysphagia; haematemesis; rectal bleeding;
haematuria; haemoptysis; neck lump; weight
loss; night sweats; breast lump; breast pain;
nipple discharge or breast skin changes; inter-
menstrual bleeding; post-menopausal bleeding;
post-coital bleeding; first occurrence of a
venous thromboembolism; bruising; cough.
●
aTypes of prediction model studies for each model defined according to the TRIPOD [17] guidelines. 1a – Development only; 1b – Development and validation using resampling; 2a – Random split-sample development
and validation; 2b – Nonrandom split-sample development and validation; 3 – Development and validation using separate data; 4 – Validation study
bIf anaemia was defined by a haemoglobin value, it was considered an investigation. Self-report of anaemia in the absence of a blood test was considered a symptom
cSelvachandran 2002 [30] describes a copyrighted model, the Weighted Numerical Score (WNS) that is incompletely reported
dspecifically blood mixed with/on stool
especifically rectal bleeding independent of straining or defaecation, blood clots, or dark red blood
fin addition to documentation of these symptoms, prescriptions used as a proxy. Laxative prescriptions taken to indicate constipation, anti-diarrhoeal prescriptions diarrhoea, and antispasmodic prescriptions
abdominal pain
Table 2 Variables included in risk models and TRIPOD classification of studies examining model performance (Continued)
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Fig. 2 Sensitivities and specificities of risk prediction models at reported thresholds. ● indicates performance in a development population, ■ in
an internal validation, and black triangle in an external validation (referenced). CRC – colorectal cancer. WNS – weighted numerical score
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Although the aim of this review was not to assess the per-
formance of referral guidelines for CRC, five papers [11,
24, 30, 34, 35] simultaneously compared the performance
of risk models with that of published guidelines.
Four compared the sensitivity and specificity of the
WNS to UK national or regional guidelines (Fig. 4): in three
[11, 30, 34] a threshold of 50 or 60 in the WNS had a
higher sensitivity and specificity than the guidelines, and in
the fourth [35] a threshold of 60 had similar performance
to both the NICE consultation guidelines published in 2004
[36] and the 2000 Department of Health [37] guidelines.
Figure 4 also shows Marshall et al.’s [24] study which
compared the BB equation and CAPER score to three
variations of NICE guidance in the UK THIN primary
care database. They found the sensitivity and specificity
of both risk models to be similar to the NICE 2005
guidelines [38]; however the authors also report the dis-
crimination and show that both models outperformed
the NICE guidelines with AUROCs of 0.83 (BB Equation)
and 0.79 (CAPER Score), compared to 0.65 for the best
performing interpretation of NICE guidelines. The same
study [24] also compared the discrimination of the BB
equation, CAPER score and NICE guidelines in a primarycare case-control study with participants recruited from
21 practices in the UK. Again, the AUROCs achieved by
the BB Equation (0.92) and CAPER Score (0.91) were sig-
nificantly higher than the best performing interpretation
of NICE guidelines (0.76).
Discussion
Strengths and weaknesses
The main strengths of this review are the broad search
strategy and the systematic approaches used to identify
studies and extract data. However, as with all systematic
reviews, our conclusions are limited by the quality of
published research. The included studies were heteroge-
neous in design, setting and duration of follow-up. Add-
itionally, although we only included risk models with
published performance data, two only provided positive
predictive values, only six have been validated in external
populations, and only one has been assessed for clinical
utility or impact. This tendency for research into risk
prediction tools to focus on model development ra-
ther than validation and impact is well documented
[39, 40]. Nevertheless, it limits the conclusions that
can be made about the potential role of these risk
models in clinical practice.
Fig. 3 Area Under the Receiver Operating Characteristic curve of risk prediction models. ● indicates performance in a development population,
black diamond in bootstrap resampling, ■ in an internal validation, and black triangle in an external validation (referenced). Point colours correspond to
study design; red represents case-control, green cross-sectional and yellow cohort studies. CRC– colorectal cancer. WNS – weighted numerical score
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Where data on discrimination and accuracy was re-
ported there is little to distinguish between the models
developed and validated in primary care. The four
QCancer® models [25–27] were developed and validated
using prospective cohort designs within two large UK
primary care record databases, QResearch (develop-
ment) and THIN (validation). All contain a combination
of demographic, symptom, and investigation variables
routinely recorded in electronic medical records, and all
have AUROCs above 0.89 in either split-sample or exter-
nal validation, and sensitivities around 0.7 with specific-
ities over 0.95. The BB equation was also developed in
the THIN database but using a case-control design
[24] and has been validated in a dataset of paper-
based primary care records from 21 English primary
care practices, whilst the CAPER score was developed
from those same primary care records and validated
in the THIN database [24]. Both the BB equation and
CAPER score performed better in the primary care
record dataset, achieving comparable AUROCs and
sensitivity and specificity to the QCancer® models. As
Marshall et al. [24] describe, reasons for this mayinclude the fact that clinical features of colorectal cancer
were identified from both paper and electronic records
and included analysis of free text in the primary care rec-
ord dataset. The use of case-control designs instead of
cohort studies for both the development and validation of
these risk models, however, means that these measures
may not accurately reflect their performance in population
based cohorts due to the wide dispersion of risk factors in
the cases and controls and the restricted distribution of
matched variables.
Additionally none of these models have been validated
outside data routinely collected by General practitioners
(GPs). It is known that some symptoms are more likely
to be recorded by a GP in patients in whom cancer is
suspected. For example, patients coded as having a
change in bowel habit are at greater risk than those with
diarrhoea or constipation [41]. As a result of this coding
bias it is likely that the recorded symptoms used in these
models overestimate the significance of those symptoms in
the presenting population. Whilst all these models in pri-
mary care can therefore accurately discriminate between
patients in whom GPs have or have not chosen to routinely
record these symptoms and could be used to identify those
Fig. 4 Sensitivities and specificities of risk prediction models and
guidelines within the same population. Highlighted boxes indicate
guidelines. In NICE 1, 2 and 3 a score of 1 was given for fulfilling any
of the NICE high-risk criteria and a score of 100 for a positive faecal
occult blood test (FOBT), abnormal rectal examination or abdominal
mass. For NICE 1 a single consultation with diarrhoea or change in
bowel habit (CIBH) was assumed to indicate a 6 week change. For
NICE 2 two consultations for diarrhoea between 35 and 119 days
apart were taken to indicate a change in bowel habit for > 6 weeks
(CIBH coding not used). For NICE 3 two consultations for diarrhoea
between 35 and 119 days apart, or a single consultation with CIBH,
were taken to indicate a change in bowel habit for > 6 weeks. WNS
– Weighted Numerical Score developed by Selvachandran et al.
2002 with cut-offs of 40, 50, 60 or 70. DOH – Department of Health
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they perform in the consultation setting when GPs
are having to decide whether the patient in front of them
does or does not have a given symptom is not known.
Models developed and validated in secondary care set-
tings were instead all based on cross-sectional studies of
patients referred with symptoms of CRC with datacollected using patient and/or physician questionnaires
at the time of investigation. All have similar discrimin-
ation (AUROC 0.8 to 0.9) in development populations,
but the only model to be externally validated is the WNS
developed by Selvachandran et al. [30]. This has been vali-
dated in four separate populations with a prevalence of
CRC of around 5 %. The AUROCs range from 0.76 [35] to
0.86 [30] and sensitivity and specificity from 0.96 and 0.40
to 0.64 and 0.82. A low threshold, with a high sensitivity,
could therefore be used to identify those in whom further
investigation is not required. However, all the patients in-
cluded in these studies had already been assessed as high
risk by primary care physicians so the score would be
likely to perform less well in an un-referred primary care
population, therefore validation in that setting is required.
Implications for clinicians and policy makers
The risk models identified in this review have the potential
to improve the diagnosis of CRC by helping clinicians to
identify those patients presenting with symptoms of
possible CRC in whom further investigation and referral is
most appropriate. The potential advantages of risk
prediction models in this context are that they can in-
clude combinations of symptoms and other risk factors,
and different thresholds for action can be used. For ex-
ample, a threshold with high sensitivity and high specifi-
city could be used to define a high risk patients that
require urgent referral, whilst one with very high sensitiv-
ity and low specificity could be used to identify those who
do not require further investigation at that time.
Sackett and Haynes [42] identified four questions
which must be addressed before incorporating diagnostic
tests into clinical practice, however. The first three are
concerned with test performance: whether test results
are different between those with and without the condi-
tion; whether patients with certain test results are more
likely to have the target disorder; and whether the test
results distinguish patients with and without the target
disorder. This review shows that risk models for CRC do
exist which meet these criteria, with the best performing
having sensitivities above 0.7, specificities above 0.9 and
AUROCs over 0.9 in external validation studies.
Most contain variables that are easily obtainable in a sin-
gle consultation and so could relatively easily be incorpo-
rated into practice. Whether any of them are any better
than a clinician’s assessment is, however, uncertain. In the
only study to compare a risk model with clinical judgement
[30] the WNS was compared to the specialist clinical
assessment of a comprehensive questionnaire-gathered
history and there was no significant difference in dis-
crimination. There is more evidence to suggest that
the models are better than previous referral guidelines.
Although not the primary aim of this review, in all cases
where models were compared with guidelines the
Williams et al. BMC Gastroenterology  (2016) 16:63 Page 14 of 16predictive models showed better discrimination and
equal or better accuracy [11, 24, 30, 34, 35].
Unanswered questions and future research
This review also cannot answer Sackett and Hayne’s
fourth question - whether patients undergoing the diag-
nostic test fare better than similar untested patients. No
studies have sought to address that. Before incorporating
any of these risk models into practice, further research is
therefore needed to validate the most promising models
in clinical settings in comparison to clinical judgement
and current referral guidelines, and to assess the impact
of the use of these risk models in practice. Further work
is also needed to consider whether CRC alone or in
combination with advanced colorectal neoplasia or ad-
enoma is the most appropriate outcome. This review fo-
cused on risk prediction models for CRC and only two
models, which both reported only limited performance
data and have not been validated, included advanced colo-
rectal neoplasia or adenoma in addition to CRC [20, 28].
It is, therefore, not possible from this review alone to
know how the performance of models predicting the
combined outcome of advanced colorectal neoplasia
and CRC compares to those with CRC as a single
outcome. One study, however, reported the perform-
ance of risk models for CRC, advanced adenoma, or
adenomas 6–9 mm in diameter separately within the
same population [31]. The discrimination for the CRC
model was substantially better (AUROC 0.87 compared to
0.70 and 0.67 for advanced adenoma and adenomas
6–9 mm in diameter respectively). This probably reflects
the fact that many adenomas are asymptomatic and so
identified less well by risk prediction models developed in
symptomatic populations. The discriminatory perform-
ance for advanced adenoma in this symptomatic popula-
tion is comparable with risk models developed for
asymptomatic individuals [43]. This suggests that models
with a combined outcome of advanced colorectal neopla-
sia and CRC may identify those with CRC less well than
models with CRC as a single outcome. However, it is
widely accepted that CRC arises from the adenoma-
carcinoma sequence and so identification of patients with
advanced colorectal neoplasia has the potential to reduce
future incidence of invasive CRC. The choice of out-
come(s) therefore depends on the purpose for which the
risk models are to be used. If the priority is identification
of patients with prevalent CRC, then a risk model includ-
ing CRC as the sole outcome is likely to have the greatest
discrimination and accuracy and allow targeting of refer-
rals and further investigations most effectively. If the pri-
ority is instead to identify both prevalent CRC and those
patients at high risk of developing CRC in the future, then
a risk model including advanced colorectal neoplasia
would be more appropriate.The introduction of a two-step process into the re-
cently updated NICE referral guidelines [44], in which
the referral decision for individuals at intermediate risk
is made based on the result of testing for occult blood in
faeces, also provides an opportunity for research into in-
corporating other pre-referral tests into risk models.
These include faecal immunochemical tests [16] and po-
tentially more specialised tests, such as exfoliated DNA
and carcinoembryonic antigen (CEA), which were of
predictive value in secondary care developed models.
From work in other disease areas [45–49] we know that
uncertainty about how to account for risk factors perceived
to be important but not included in the tools, and the per-
ception that clinical judgement is as good as or better than
risk tools, contribute to the low uptake of risk models.
Practical issues such as lack of time, poor knowledge or
understanding of the tools, and poor computer soft-
ware also restrict model use. Additionally, a recent study
using simulated consultations with risk prediction tools
for cancer has shown that clinicians may interpret symp-
toms inconsistently, leading to inaccurate and unreliable
cancer risk assessment, and GPs were reluctant to use the
tools for fear of alarming their patients if the risk informa-
tion is presented too explicitly [50]. Research is therefore
also needed to understand how best to incorporate risk
prediction models into routine practice, including com-
munication of risk information to patients, and to address
the barriers to their use.
Conclusions
To our knowledge this is the first systematic review of risk
prediction models for CRC in symptomatic populations.
We have shown that 15 models have been developed
across both primary and secondary care populations. Many
of these have good discrimination (AUROC > 0.85) and
most contain variables that are easily obtainable in a single
consultation. However, only six have been validated in ex-
ternal populations, and only one model has been assessed
for clinical utility in a single before and after study with no
control group. Further research is therefore needed before
they can be incorporated into routine clinical practice.
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